Abstract
Anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies were first described in 2009 and implicated in the pathogenesis of idiopathic membranous nephritis (IMN). This was a significant advance given that until then, the pathogenesis of IMN was unclear and differentiation from secondary membranous nephritis could be challenging. Since this initial study describing the anti-PLA2R antibody, several other investigators have confirmed the association of this autoantibody with IMN. Furthermore, anti-PLA2R antibodies correlate with clinical outcomes and can be used to measure response to treatment. Therefore, anti-PLA2R autoantibodies have promising applications to the diagnosis, monitoring, and treatment of IMN.
Original language | English |
---|---|
Title of host publication | Autoantibodies, Third Edition |
Publisher | Elsevier |
Pages | 545-552 |
Number of pages | 8 |
ISBN (Electronic) | 9780444563781 |
ISBN (Print) | 9780444593771 |
DOIs | |
State | Published - 1 Jan 2014 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2014 Elsevier B.V. All rights reserved.
Keywords
- Anti-phospholipase A2 receptor antibodies
- lupus nephritis
- membranous nephropathy
- phospholipase A2 receptor
- podocytes
- systemic lupus erythematosus